GIOTRIF®'s (afatinib's) clinical resource library contains a wealth of information, from a detailed bibliography of clinical data and real-world evidence publications, to videos and expert opinions to support you in prescribing GIOTRIF® (afatinib) in your eligible patients.
Effective Dose Modification
Watch a summary of RealGiDo study – a real-world analysis of GIOTRIF® (afatinib) dose modification.
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Wu YL et al. Lancet Oncol 2014.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.